We examined the effect of blocking the erythropoietin (Epo) signaling using an anti- Epo 
Introduction
Erythropoietin (Epo), a principal cytokine involved in erythropoiesis, has been reported to promote the growth of malignant tumors by binding to its receptor (EpoR) through both autocrine stimulation of malignant cells themselves and paracrine route to the feeding microvessels due to the expression of both transcripts for Epo and EpoR mRNA in very many cancers [1] [2] [3] [4] and for EpoR mRNA in the human endothelial cells of vein and artery [5] . However, there is controversy over the EpoR in cancer patients to be functional to develop their malignancies.
Preclinical studies clarified that blockade of the Epo signal in resected specimens [6] , xenografts [2] or tumor chamber [7] using anti-Epo antibody, soluble form of EpoR (sEpoR) capable of binding to Epo, EpoR antagonists [6] or pharmacologic JAK2 inhibitor [7] led to their destruction. The involvement of Epo in malignancies has been shown by transfection of Epo agonist R103A-Epo [8] or constitutively active EpoR-R129 [9] into rat mammary carcinoma cells. The major signaling pathways involved in hematopoiesis are the JAK2 and STAT5 [10] [11] [12] , the PI3K/AKT [13] [14] [15] [16] and the ERK/MAPK [17] routes for survival and/or proliferation. The JAK2 and STAT5 route is detected in female reproductive organ malignancies [6] , in xenografts of melanoma and stomach choriocarcinoma cell lines [2] and in a prostate cancer cell line [18] ; and, the ERK/MAPK route is seen in mammary carcinoma [8, 9] and astrocytoma [19] . Both the STAT5 and the AKT routes are in operation in neuroblastoma cells [20] .
Recently chronic stress and other behavioral conditions have been reported to cause promotion and progression of cancers; catecholamines in ovarian cancers [21, 22] , muscarinic cholinergic receptors in prostate [23] , colon [24] , mammary carcinoma cells [25, 26] , and the receptors and ligands in small cell lung carcinoma [27, 28] were shown to promote their growth and angiogenesis.
To develop more effective treatment [1, 2, 6] , we transfected seven cancer cell lines, SCH, HepG2, A549, SBC3, HeLa, P39 and PC-3 to express constitutively active sEpoR and implanted them in nude mice. We report here that constitutive secretion of sEpoR suppressed the tumor size of all xenografts except for those of P39 and that the present device revealed the blockade of promotion pathways in all xenografts; less numerous viable and proliferating cells led to severe reduction of vascular densities in the transfected xenografts compared with those in controls. Moreover, at the time of extirpation of the tumors, the hematocrit volumes reflected the secretion amount of Epo in the cell lines before implantation and were comparable in both hosts implanted with transfected or wild-type cells. Furthermore, Epo and EpoR mRNAs and receptors for  1A -adrenaline ( 1A -ADR) and m3-AchR mRNAs were expressed in all non-transfected cell lines and upregulated in all xenografts except for A549. The constitutive activation of ERK/MAPK was reduced in the transfected cell lines, but upregulated through noradrenaline and/or acetylcholine exposure. Taken together, the present Epo deprivation may be substantially effective to block autocrine and paracrine stimulation of Epo in cancers but the neurotransmitters produced in the host by stress may interfere with this antitumor activity.
Materials and Methods

Transfection of cDNA for sEpoR and Western Blotting
We prepared a cDNA coding for the Igκ signal sequence followed by 4 aa (Ala-Arg-Val-Val) after signal cleavage synthetically with Nhe I site introduced at the 5' end (fragment 1). A cDNA encoding most part of extracellular region of human EpoR with Bgl II site introduced at the 3' end was amplified by the PCR (fragment 2). A DNA fragment coding for Histidine-tag (His) 6 was generated by digestion of pQE60 (Qiagen, Hilden, Germany) with Bgl II and Hind III (fragment 3). These fragments were cloned in tandem into the Nhe I and Hind III site of pcDNA3.1(-) (Invitrogen, Carlsbad, California, U.S.A.). The resulting plasmid, sEpoR-(His) 6 /pcDNA3.1, produces a soluble (secreted) form of EpoR (aa 3 to 226) with five additional aa Ala-Arg-Val-Val-Ala at the N-terminal and Arg-Ser-(His) 6 at the C-terminal ends. Seven cell lines, SCH, HepG2, A549, SBC3, HeLa, P39 and PC-3, were maintained in the conditions described previously [2] and were transfected with the expression vector for sEpoR-(His) 6 (typically 0.67 μg for 3.5 cm dish) using Lipofectamine Plus (Life Technologies, Rockville, Maryland, U.S.A.) according to the manufacturer's recommendations. After selection with 500 μg/ml G418 (Life Technologies) for 10-14 days, the resistant clones were isolated and expanded. The positive cell line secreting sEpoR was screened by adding Nin-ta agarose (Qiagen) to the supernatant (1 ml) of each clone to immobilize the His-tagged sEpoR, incubated for 1 h at room temperature, and washed 3 times with phosphatebuffered saline. Proteins were then eluted in loading buffer by boiling and subjected to 15% SDS-PAGE. After transfer onto a polyvinylidene difluoride membrane (Millipore, Billerica, MA, U.S.A.), proteins were detected with an antiserum raised against the N-terminal region of sEpoR (gifts from Dr. Masaya Nagao). Anti-Epo monoclonal antibody (Genzyme, Cambridge, MA, U.S.A.) was used to detect Epo bound to the secreted sEpoR-(His) 6 .
Tumor Formation
All animal experiments were approved by the institution and performed under guidelines of the Kinki University Animal Facilities. A total of 70 male mice (BALB/cA Jcl-nu/nu, CLEA, Tokyo, Japan) were injected wild or transfected 2 × 10 6 -4 × 10 6 cells/0.1 ml of each corresponding medium subcutaneously into interscapular region of each mouse at 6-8 weeks of age. We designated the transfected cell lines sSCH, sHepG2, sA549, sSBC3, sHeLa, sP39 and sPC-3. After 4 -12 weeks of the implantation, the mice were killed under deep anesthesia, withdrawn, if possible, about 0.8 ml of whole blood from the heart and extirpated the tumors. The blood specimens were used for determination of the hematocrit volumes and the serum Epo levels by the methods described pre-viously [2] . All extirpated tumors were cut into 1 mm-thick slices and processed for biochemical and morphological examinations.
Immunohistochemistry
The methods used for immunostaining of the cryosections of xenografts were as described previously [1] . We used the following primary antibodies: anti-EpoR (1:50) [29] , anti-FVIII (DAKO, 1:500) and anti-PCNA (Santa Cruz, California, U.S.A., 1:50) antibody. To detect apoptosis, we used an in situ apoptosis detection kit (Intergen, Norcross, GA, U.S.A.).
For immunoelectron microscopy, cell lines were fixed in 2% paraformaldehyde and 0.1% glutaraldehyde solution, dehydrated and embedded in LR white (Nisshin EM, Tokyo, Japan). The 70 nm sections were treated with a sEpoR antibody at 4˚C overnight, exposed to 10 nm goldlabelled anti-rabbit antibody (BB international, Cardiff, UK) at 37˚C for 1h, and then processed for examinations with a H-7100 electron microscope (Hitachi, Japan).
Quantitative RT-PCR Analysis
To confirm the expression levels of Epo, EpoR,  1A -ADR and m3-AchR mRNA in xenografts, the frozen slices were homogenized and processed for measurements by real-time quantitative RT-PCR with an ABI PRISM7700 sequence detection system (Applied Biosystems, Foster, CA, U.S.A.). All PCR reactions were performed with Quantitative PCR Supermix-UDG (Invitrogen) in a 25 µl final mixture. PCR primers of Epo and EpoR were described previously [2] ; primers of  1A -ADR sequences were FW primer TCGGACTCGGAG-CAAGTG and RV primer, CATCCCGCTGCCTCCTG, reporter prove, ACGCTCCGCATCCAT, and m3-AchR (CHRM3, Assay ID HS00265216_sl). 18S rRNA primers and probes were supplied by Applied Biosystems as TaqMan Gene Expression Assays and TaqMan Ribosomal RNA Control Reagents (VIC TM prove).
ERK/MAPK Assay
Cell lines with or without transfection were starved in serum-free medium for 24 h and either left unstimulated or incubated with 4 µM noradrenaline (Sankyo, Tokyo, Japan) or 300 µM acetylcholine (Sigma Aldrich, St. Louis, MO, U.S.A.) for 10 min at 37˚C. Whole cell extracts were resolved by SDS-PAGE and subjected to immunoblotting using ERK1/2/MAPK, phospho-ERK1/ 2/MAPK and -actin antibody (Cell Signaling Technology, Danvers, MA, U.S.A.).
Statistics
The Student's t-test was used to determine a significant difference in vascular density and in transcriptional levels, and a  2 test, to compare the incidence of cell population. Differences with P values less than 0.05 were considered significant.
Results
Stable Transfection of the cDNA for sEpoR
The supernatant of the sHepG2 and sA549 showed the band for sEpoR protein as seen in the control, UT-7, but not the band for Epo protein (Figure 1(A) ). Addition of rhEpo to the supernatant and the medium showed positive and negative bands, respectively (Figure 1(A) ). The band intensity of anti-Epo antibody was confirmed by dissolving 0.1 μg or 2 μg of rhEpo in loading buffer processed for blotting, which showed comparable intensity implying that the sEpoR entrapped almost 2 μg rhEpo (Figure 1(A) ). Additionally the bands for sEpoR were detectable in the culture media of the transfected cell lines and in the lysates of the transfected xenografts (Figure 1(B) ).
Immunoelectron microscopy revealed that sEpoR was detected more frequently in the vesicles in the cytoplasm and at the cell surface region of the sSBC3 (Figure 1(C) , (a)) than those in the SBC3 cells (Figure 1(C), (b) ). The specificity of the sEpoR antibody was confirmed with the use of antibody pretreated with antigen (Figure 1(C) , (c), (d)).
Tumor Growth
The growth of sSCH, sHepG2, sSBC3, sHeLa, sPC-3, sA549 and sP39 xenografts just before extirpation was 82%, 55%, 51%, 67%, 17%, 60% and 146% of those of non-transfected specimen, respectively (Figure 2) . The serum Epo level of the hosts generally corresponded to the secretion amount to the non-transfected cell line (Table 1, 2). The hematocrit values corresponded to the respective Epo level of the host and were comparable to those in the controls ( Table 2 ).
Microscopy
The wild-type xenografts showed characteristic morphological features such as huge cells in SCH, compact cellular arrangement in HepG2, glandular structure in A549 (Figure 3(a) ) and scattering many neutrophils and macrophages in SBC3 (Figure 3(b) ), whereas these features were disarranged in the transfected xenografts ( Figure  3(a'), (b'), (c') ). The majority of the wild-type xenografts showed central and/or focal necrosis containing sporadical apoptotic cells (Figure 3(g), (h), (i) ), while in the transfected xenografts the small stromal cancer cells were frequently detected in the dispersed architecture containing fragmented cells and cells in apoptosis (Figure 3(g' ), (h'), (i')). In most control xenografts the immunoreactive EpoR appeared as homogeneously stainable cytoplasm of the cancer cells (Figure 3(j) , (k), (l)), and in transfected xenografts, it was frequently seen as grains in strong positive cytoplasm (Figure 3(j' ), (k'), (l')). 
Suppression of Viable and Proliferating Cells
The cell population with proliferating, chromatin-condensed, small or large vacuolated and normal nuclear features is arranged in Figure 4 . The dying cells with *The methods for determination were described previously (Yasuda, 2003) . vacuolated or without nucleus were significantly more numerous in all transfected than in all wild-type specimen (P < 0.001, Figure 4 ). The cells with chromatincondensed nuclei were significantly more numerous in sHepG2, sA549, sSBC3, sP39 and sPC-3 xenografts (P < 0.001, Figure 4 ) than respective controls. There were significantly fewer proliferating cells in the transfected xenografts than in the wild-type specimens (P < 0.001, P < 0.01, P < 0.05, Figure 4 ). The suppression of proliferating cells was in the decreasing order of sSBC3, sA549, sPC-3, sHeLa, sHepG2, sSCH and sP39 xenografts. The population of normal cells decreased significantly in xenografts of sA549, sSBC3, sHeLa and sP39 compared with the controls (P < 0.001, P < 0.01, Figure 4 ).
Suppression of Angiogenesis
The capillaries with or without lumen showing positive immunoreactivity to anti-FVIII antibody (Figure 5(a) ) were counted at the peripheral, intermediate and central regions separately and the data is summarized in Figure  5(b) . The capillary endothelial cell extension of all xenografts with transfection was broken into short fragments, especially in the intermediate zones (Figure 5(a) ), whereas those of controls they extended between the cells and between the intervening fibrous tissues without interruption ( Figure 5(a) ). There were significantly more vessels in the wild-type than in transfected xenografts (P < 0.001, P < 0.01, P < 0.05, Figure 5(b) ). The reduction of vascular density was calculated by comparing the total number of capillaries in wild-type xenografts with those in transfected xenografts. The reduction of vascular density in xenografts of sPC-3, sP39, sHepG2, sHeLa, sSCH, sA549 and sSBC3 was 74.5%, 74.2%, 60.2%, 60.2%, 57.6%, 50.0% and 48.9%, respectively. The xenografts of PC-3 showed the highest vascularity and those of its transfected counterpart, sPC-3 the greatest reduction ( Figure 5(b) ), while those of SBC3 showed the lowest vascularity and sSBC3 the least reduction ( Figure 5(b) ). Thus, reduction in vascular density was in the decreasing order of PC-3, P39, HepG2, HeLa, SCH, A549 and SBC3.
Expression of Epo and EpoR mRNA in Xenografts
Excluding SCH and SBC3 that expressed markedly higher Epo mRNA in both cell lines and xenografts than others, Epo mRNA was expressed significantly higher (P < 0.001, P < 0.05, Figure 6 (a)) in the xenografts than the respective cell line except for A549, and it was up-regulated in sSCH and sHepG2 xenografts (P < 0.05, < 0.001, Figure 6 (b)). P EpoR mRNA was expressed approximately 10 3 times more than Epo mRNA in all cell lines (Figure 6(c) ). In the majority of wild-type xenografts, the EpoR mRNA levels were significantly higher than in the respective cell lines (P < 0.001, P < 0.05, Figure 6(c) ), while in HeLa and SBC3, it was suppressed significantly compared with the cell line (P < 0.05, P < 0.001, Figure 6(c) ). EpoR mRNA was down-and up-regulated in xenografts of sHepG2, sA549 and sHeLa, respectively (P < 0.001, P < 0.05, Figure 5(d) ). Up-regulation of Epo and EpoR mRNA may be due either to the hypoxic microenvironment in xenografts or the participation of capillary endothelial cells from the hosts in xenografts, respectively.
Expression of  1A -ADR and m3-AchR mRNA
All cell lines except for SCH expressed both mRNAs, and SBC3, A549, P39 and PC-3 cell lines expressed prominently both or either mRNA (Figure 7(a), (b) ). In wild-type xenografts, both mRNAs were upregulated in PC-3 compared with the respective cell line.  1A -ADR mRNA was upregulated in HepG2 and comparable in A549 and SBC3 (Figure 7(a) ) and m3-AchR mRNA was downregulated in A549 and P39 (P < 0.001, P < 0.05, Figure 7(b) ) and upregulated in SBC3 (P < 0.01, Figure  7(b) ) xenografts compared with the respective cell line.
In transfected xenografts, downregulation of the  1A -ADR mRNA was detected in the sSCH and sSBC3 (P < 0.05, P < 0.001, Figure 7(c) ), and downregulation of m3-AchR mRNA was seen in the sSCH and sA549 (P < 0.001, Figure 7(d) ), whereas, in the sSBC3, it was raised significantly (P < 0.001, Figure 7(d) ) compared with the wild-type xenograft. 
Phosphorylation of ERK/MAPK
Participation of the ERK/MAPK pathway in proliferation [8, 9] of the wild-type cell lines was examined. Most cell lines showed the band for constitutive phospho-MAPK in various intensities except for PC-3 (Figure 8(a) ). In three of the five paired cell lines with or without transfection, the band intensity of constitutive phospho-MAPK was weak in the transfected cell line but was regained after exposure to noradrenaline and/or acetylcholine ( Figure  8(b) ), implicating the suppression of phosphorylation of ERK/MAPK through sEpoR may be modulated through either or both neurotransmitters in the transfected cell lines.
Discussion
Intercaption of the Epo signal in the blocks of malignant clinical specimens in vitro [6] , in their xenografts [1] and in the xenografts of cancer cell lines in nude mice [2] by local or intraperitoneal injections of anti-Epo antibody, sEpoR or EpoR antagonist reduced the tumor masses from macroscopically detectable destruction to microscopical changes. Additionally, the present device induced the significant suppression of the survival and proliferation of the malignant cells and the angiogenesis in all transfected-xenografts compared with those shown in wild-type xenografts in spite of possible interference with autonomic neurotransmitters from the hosts.
The malignant cells expressing EpoR through blockade of Epo signaling appear to die by a mechanism similar to that seen in HCD 57 cell line, the survival of which depends entirely on the Epo signal [30] , in which deprival of Epo induces the reduction of receptor internalization leaving EpoR in the cytoplasmic membrane. In this study, stronger reactivity to the EpoR antibody was seen in the intact and degenerating malignant cells of the transfected than in those of wild-type xenografts indicating the addition of the secreted sEpoR in the transfected cells to the original EpoR (Figure 3(j), (k), (l) ). The population of dead cells was significantly higher than in each control xenograft (Figure 4 , P < 0.001) and when the cells with chromatin-condensed nuclei that are suggestive of precursor of apoptotic death were added, the viability of the majority of transfected xenografts was less than 50 %, showing sSBC3, sA549, sPC-3, sP39, sHepG2, sSCH and sHeLa xenografts in high reduction order.
Since the level of EpoR mRNA implicates the vascular density of the tumor in the host, we supposed that tumor growth would be promoted by higher expression of EpoR in the malignant cells. We determined the expression levels of both Epo and EpoR mRNA in 24 malignant cell lines (Yasuda et al., submitted) . The expression levels of the EpoR mRNA were in the decreasing order of PC-3, P39, HeLa, SBC3, A549, HepG2 and SCH. The number of proliferating cells in the xenografts (Figure 4 ) was not correlated with the EpoR expression of the cells ( Figure  6C ), but the vascular density was correlated with the EpoR levels in the wild-type xenografts except for SBC3 and A549 (Figure 5, 6(c)) ; The reduction in vascular density was in the decreasing order of PC-3, P39, HeLa, HepG2, SCH, A549 and SBC3 xenografts, and the reduction in angiogenesis was in the decreasing order of sPC-3, sP39, sHepG2, sHeLa, sSCH, sA549 and sSBC3 ( Figure 5) . The expression level of EpoR mRNA was significantly lower in SBC3 or comparable in A549 xenografts than in their respective cell lines (P < 0.001, Figure 6(c)) .
Recently neurotransmitters and their ligands have been reported to regulate the proliferation, apoptosis and metastasis of many cancers and cancer-related angiogenesis [31, 32] ; small cell lung carcinoma [27] and squamous cell lung carcinoma [33] express AchRs with choline acetyltransferase and while in lung adenocarcinoma, β 1 -and β 2 -ADR [34] . This neurotransmitter-mediated proliferation is regulated via activation of ERK1/2 (phosphorylation of MAPK) [32, 35] . In the present study, expression of  1A -ADR and m3-AchR mRNAs was significantly higher in most xenografts (Figure 7 ) and the constitutive activation of ERK/MAPK was suppressed in transfected cell lines except for A549 and PC-3 ( Figure  7(b) ). Exposure to noradrenaline and/or acetylcholine activated the ERK/MAPK in wild-type and transfected cell lines. Taken together, the neurotransmitters considered to be produced by stress in the host may interfere with the antitumor activity and modulate the proliferation of malignant cells in xenografts.
In conclusion, constitutively activated sEpoR of malignant cell lines appears to abolish the autocrine and paracrine Epo on malignant cells and reduce the capillary endothelial cells leading to decrease in proliferating and viable cells, thus causing severely damaged angiogenesis in the tumors, but this anti-tumor activity can be affected by neurotransmitters from the host.
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